Morphiex Biotherapeutics | Morphiex CEO to Present at the 2020 CD47|SIRPa Summit
587
post-template-default,single,single-post,postid-587,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-content-sidebar-responsive,qode-theme-ver-13.8,qode-theme-bridge,disabled_footer_top,disabled_footer_bottom

Morphiex CEO to Present at the 2020 CD47|SIRPa Summit

Our CEO, Dr. Anthony Schwartz will be speaking at the 2020 CD47|SIRPa Summit to discuss the advantages of targeting SIRPa and thrombospondin-1 for the treatment of cancer. Morphiex’s lead candidate (MBT-001) is the only drug that targets both SIRPa and thrombospondin-1.  #CD47 #SIRPalpha #cancer #immunotherapy

https://www.cd47sirpa.com/



Location

240 Newbury Street, 2nd Floor
Boston, MA
info@morphiex.com

Social Media

Twitter Facebook LinkedIn